Amorfix second quarter net loss decreases to $25,728 Amorfix Life Sciences, something development company focused on the development of diagnostics and therapeutics for misfolded protein diseases, announced its operational and financial results for the three and half a year ended September 30 today, 2010. We have become happy with the steady improvement we’ve made this one fourth on all of our diagnostic and therapeutic applications, stated Dr 40 mg Cialisu . Robert Gundel, Chief Executive Officer of Amorfix. We have achieved significant milestones for our A4 assay and can continue to work diligently to develop the A4 preclinical service revenue while, in parallel, advancing the development of our human being diagnostic test for Alzheimer’s disease.